S&P 500   3,641.26 (+0.32%)
DOW   29,918.64 (+0.15%)
QQQ   299.77 (+1.18%)
AAPL   117.02 (+0.85%)
MSFT   216.13 (+1.06%)
FB   278.25 (+0.97%)
GOOGL   1,791.59 (+1.56%)
AMZN   3,210.68 (+0.80%)
TSLA   595.79 (+3.80%)
NVDA   532.50 (+0.59%)
BABA   276.49 (-0.44%)
CGC   27.33 (+1.71%)
GE   10.40 (-0.95%)
MU   64.31 (+1.39%)
AMD   87.31 (+0.69%)
T   28.94 (-0.17%)
NIO   54.04 (+0.65%)
F   9.06 (-0.22%)
ACB   8.83 (+1.38%)
NFLX   489.13 (+0.85%)
GILD   59.69 (+0.32%)
BA   218.03 (+0.19%)
DIS   147.90 (-0.80%)
S&P 500   3,641.26 (+0.32%)
DOW   29,918.64 (+0.15%)
QQQ   299.77 (+1.18%)
AAPL   117.02 (+0.85%)
MSFT   216.13 (+1.06%)
FB   278.25 (+0.97%)
GOOGL   1,791.59 (+1.56%)
AMZN   3,210.68 (+0.80%)
TSLA   595.79 (+3.80%)
NVDA   532.50 (+0.59%)
BABA   276.49 (-0.44%)
CGC   27.33 (+1.71%)
GE   10.40 (-0.95%)
MU   64.31 (+1.39%)
AMD   87.31 (+0.69%)
T   28.94 (-0.17%)
NIO   54.04 (+0.65%)
F   9.06 (-0.22%)
ACB   8.83 (+1.38%)
NFLX   489.13 (+0.85%)
GILD   59.69 (+0.32%)
BA   218.03 (+0.19%)
DIS   147.90 (-0.80%)
S&P 500   3,641.26 (+0.32%)
DOW   29,918.64 (+0.15%)
QQQ   299.77 (+1.18%)
AAPL   117.02 (+0.85%)
MSFT   216.13 (+1.06%)
FB   278.25 (+0.97%)
GOOGL   1,791.59 (+1.56%)
AMZN   3,210.68 (+0.80%)
TSLA   595.79 (+3.80%)
NVDA   532.50 (+0.59%)
BABA   276.49 (-0.44%)
CGC   27.33 (+1.71%)
GE   10.40 (-0.95%)
MU   64.31 (+1.39%)
AMD   87.31 (+0.69%)
T   28.94 (-0.17%)
NIO   54.04 (+0.65%)
F   9.06 (-0.22%)
ACB   8.83 (+1.38%)
NFLX   489.13 (+0.85%)
GILD   59.69 (+0.32%)
BA   218.03 (+0.19%)
DIS   147.90 (-0.80%)
S&P 500   3,641.26 (+0.32%)
DOW   29,918.64 (+0.15%)
QQQ   299.77 (+1.18%)
AAPL   117.02 (+0.85%)
MSFT   216.13 (+1.06%)
FB   278.25 (+0.97%)
GOOGL   1,791.59 (+1.56%)
AMZN   3,210.68 (+0.80%)
TSLA   595.79 (+3.80%)
NVDA   532.50 (+0.59%)
BABA   276.49 (-0.44%)
CGC   27.33 (+1.71%)
GE   10.40 (-0.95%)
MU   64.31 (+1.39%)
AMD   87.31 (+0.69%)
T   28.94 (-0.17%)
NIO   54.04 (+0.65%)
F   9.06 (-0.22%)
ACB   8.83 (+1.38%)
NFLX   489.13 (+0.85%)
GILD   59.69 (+0.32%)
BA   218.03 (+0.19%)
DIS   147.90 (-0.80%)
Log in
OTCMKTS:COCP

Cocrystal Pharma Stock Forecast, Price & News

$1.71
+0.41 (+31.54 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.52
Now: $1.71▼
$2.07
50-Day Range
$0.80
MA: $0.90▼
$1.71
52-Week Range
$0.39
Now: $1.71▼
$3.04
Volume70.05 million shs
Average Volume3.98 million shs
Market Capitalization$117.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.38 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:COCP
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.cocrystalpharma.com
Phone+1-425-3987178
Employees11

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares68,564,000
Market Cap$117.24 million
Next Earnings DateN/A
OptionableNot Optionable
$1.71
+0.41 (+31.54 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive COCP News and Ratings via Email

Sign-up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cocrystal Pharma (OTCMKTS:COCP) Frequently Asked Questions

How has Cocrystal Pharma's stock price been impacted by COVID-19?

Cocrystal Pharma's stock was trading at $1.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, COCP shares have increased by 35.7% and is now trading at $1.71.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Cocrystal Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cocrystal Pharma.

What stocks does MarketBeat like better than Cocrystal Pharma?

Wall Street analysts have given Cocrystal Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cocrystal Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (OTCMKTS:COCP) posted its earnings results on Monday, November, 16th. The company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05).
View Cocrystal Pharma's earnings history.

What price target have analysts set for COCP?

2 Wall Street analysts have issued 12-month price targets for Cocrystal Pharma's shares. Their forecasts range from $4.50 to $5.00. On average, they anticipate Cocrystal Pharma's stock price to reach $4.75 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for Cocrystal Pharma.

Who are some of Cocrystal Pharma's key competitors?

Some companies that are related to Cocrystal Pharma include Humanigen (HGEN), Pfenex (PFNX), Novacyt S.A. (NCYT.L) (NCYT), Ergomed plc (ERGO.L) (ERGO), Silence Therapeutics plc (SLN.L) (SLN), Altimmune (ALT), Altimmune (ALT), Rafael (RFL), ProMetic Life Sciences (PLI), BELLUS Health Inc. (BLU.TO) (BLU), IMV Inc. (IMV.TO) (IMV), Unity Biotechnology (UBX), CorMedix (CRMD), CorMedix (CRMD) and Neptune Wellness Solutions Inc. (NEPT.TO) (NEPT).
View all competitors.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Bionano Genomics (BNGO), Novan (NOVN), Zosano Pharma (ZSAN), Matinas BioPharma (MTNB), Aeterna Zentaris (AEZS), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), KushCo (KSHB) and CBL & Associates Properties (CBL).

Who are Cocrystal Pharma's key executives?

Cocrystal Pharma's management team includes the following people:
  • Dr. Gary L. Wilcox, Co-Founder, Chairman & CEO (Age 73, Pay $201k)
  • Dr. Sam Lee, Co-Founder & Pres (Age 60, Pay $241k)
  • Mr. James J. Martin CPA, M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 53, Pay $231k)
  • Dr. Roger D. Kornberg, Co-Founder, Chairman of Scientific Advisory Board, Chief Scientist & Director (Age 73)

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the OTCMKTS under the ticker symbol "COCP."

Who are Cocrystal Pharma's major shareholders?

Cocrystal Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (5.48%) and Jane Street Group LLC (0.08%).
View institutional ownership trends for Cocrystal Pharma.

Which major investors are buying Cocrystal Pharma stock?

COCP stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., and Jane Street Group LLC.
View insider buying and selling activity for Cocrystal Pharma.

How do I buy shares of Cocrystal Pharma?

Shares of COCP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $1.71.

How big of a company is Cocrystal Pharma?

Cocrystal Pharma has a market capitalization of $117.24 million. Cocrystal Pharma employs 11 workers across the globe.

What is Cocrystal Pharma's official website?

The official website for Cocrystal Pharma is www.cocrystalpharma.com.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 1860 Montreal Rd, TUCKER, GA 30084-5709, United States. The company can be reached via phone at +1-425-3987178.

This page was last updated on 11/27/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.